drugset
Drugs / AVI-014
last change May 2017 re-read 2 minutes ago

AVI-014

Protein / enzyme biologic

Developed for
neutropenia
Investigated by
AviGenics

Trials 1 · a red edge is where a trial was stopped

today NCT00497809 · Ph 2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00497809 Aug 2007 → Jul 2008 breast cancer, neutropenia AviGenics Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03118492 Background May 2017 → Apr 2027 expected myelofibrosis City of Hope Medical Center Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as AVI 014 “The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF])...” NCT00497809 ↗
2

NCT03118492 ↗

NCT00497809 ↗
Modality Protein / enzyme biologic “Glycosylated Recombinant Human G-CSF AVI-014” NCT03118492 ↗
Route Intravenous “Given IV” NCT03118492 ↗